Tofacitinib as a biologic response modifier in VEXAS syndrome: A case series

The authors report no conflicts of interest. Data available upon request. Figure S1 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.